(NASDAQ: VOR) Vor Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.42%.
Vor Biopharma's earnings in 2026 is -$883,080,000.On average, 10 Wall Street analysts forecast VOR's earnings for 2026 to be -$355,589,399, with the lowest VOR earnings forecast at -$424,817,276, and the highest VOR earnings forecast at -$163,858,092. On average, 10 Wall Street analysts forecast VOR's earnings for 2027 to be -$190,669,264, with the lowest VOR earnings forecast at -$238,959,718, and the highest VOR earnings forecast at -$158,168,575.
In 2028, VOR is forecast to generate -$212,717,497 in earnings, with the lowest earnings forecast at -$272,999,286 and the highest earnings forecast at -$95,014,935.